[
  {
    "ts": null,
    "headline": "How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?",
    "summary": "Thinking about what to do with Regeneron Pharmaceuticals can feel tricky right now, and if you’re glued to the stock’s recent chart, you’re definitely not alone. After all, the company just closed at $564.63, which marks a rebound of 0.8% for the month, a small but notable bright spot set against a year-to-date decline of 21.1%. If you zoom out further, Regeneron’s journey looks even bumpier, with a 44.2% slide over the past year and a three- and five-year return both in negative territory...",
    "url": "https://finnhub.io/api/news?id=ca8f79eb3058f9579931435ef202c5af67611747529d0d0e4dede0b31d7096b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760281706,
      "headline": "How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?",
      "id": 137063785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Thinking about what to do with Regeneron Pharmaceuticals can feel tricky right now, and if you’re glued to the stock’s recent chart, you’re definitely not alone. After all, the company just closed at $564.63, which marks a rebound of 0.8% for the month, a small but notable bright spot set against a year-to-date decline of 21.1%. If you zoom out further, Regeneron’s journey looks even bumpier, with a 44.2% slide over the past year and a three- and five-year return both in negative territory...",
      "url": "https://finnhub.io/api/news?id=ca8f79eb3058f9579931435ef202c5af67611747529d0d0e4dede0b31d7096b5"
    }
  },
  {
    "ts": null,
    "headline": "DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss",
    "summary": "Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing Among three who completed speech assessments, all showed significant improvement with one able to identify one- and two-syllable words with no visual cues and respond to distant sounds and speech in noisy environments Latest DB-OTO data presented at AAO-HNSF; U.S. regulatory s",
    "url": "https://finnhub.io/api/news?id=ceb358d185cc95b723927444c9b008f8d4346abd71e2949fe039bccd21b2d77a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760278680,
      "headline": "DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss",
      "id": 137063786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing Among three who completed speech assessments, all showed significant improvement with one able to identify one- and two-syllable words with no visual cues and respond to distant sounds and speech in noisy environments Latest DB-OTO data presented at AAO-HNSF; U.S. regulatory s",
      "url": "https://finnhub.io/api/news?id=ceb358d185cc95b723927444c9b008f8d4346abd71e2949fe039bccd21b2d77a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy",
    "summary": "Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.",
    "url": "https://finnhub.io/api/news?id=d53b56705b1044b95b50659c176d0974646d5bdf39e1c289a68a2d9fefd37390",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760264280,
      "headline": "Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy",
      "id": 137063787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.",
      "url": "https://finnhub.io/api/news?id=d53b56705b1044b95b50659c176d0974646d5bdf39e1c289a68a2d9fefd37390"
    }
  }
]